Early Access of TMC207 in Patients With Extensively Drug Resistant or Pre-XDR Pulmonary Tuberculosis
Early Access of TMC207 in Patients With Extensively Drug Resistant or Pre-XDR Pulmonary Tuberculosis
The purpose of this is a study to provide early access of TMC207 to patients with pulmonary
 infection due to strains of Mycobacterium tuberculosis (M. tuberculosis) with resistance to
 isoniazid (INH), rifampin (RMP), and to a fluoroquinolone (FQ) and/or injectable second line
 tuberculosis (TB) drug (kanamycin, amikacin, or capreomycin) and who are unable/ineligible to
 participate in any other TMC207 study. In addition, information on safety and tolerability of
 TMC207 in combination with anti-TB drugs will be assessed and the results of microbiology
 assessments which are recommended to be performed during the early access study will be
 collected.
TMC207 is being investigated for the treatment of TB. TB is a contagious bacterial infection
 caused by M. tuberculosis that commonly affects the lungs, but can also affect other organs.
 Treatment of TB is protracted and burdensome and is further complicated by the emergence of
 multi-drug resistant M. tuberculosis strains. TMC207 is a diarylquinoline investigational
 compound that offers a novel mechanism of anti-TB action by specifically inhibiting
 mycobacterial adenosine triphosphate (ATP)-synthase. Multi-drug resistant TB (MDR-TB) is
 defined as infection with a strain of M. tuberculosis that is resistant to both INH and RMP
 (also known as rifampicin), two important drugs used to treat drug susceptible TB.
 Extensively drug-resistant TB (XDR-TB) is defined as MDR-TB with additional resistance to the
 most important second-line TB drugs, ie, one of the injectables (kanamycin, amikacin, or
 capreomycin) and fluoroquinolones. Pre-XDR TB is defined as MDR-TB with additional resistance
 to either a FQ or an injectable (kanamycin, amikacin, or capreomycin), but not to both a FQ
 and an injectable. Patients with either XDR-TB or pre-XDR will be included in this early
 access study. Patients who qualify for the study will be provided with a 24-week regimen of
 TMC207 which will be administered along with their background regimen (BR). BR drugs will be
 provided by the site investigator or designated study personnel in accordance with national
 TB program (NTP) guidelines. The BR should be constructed with at least 3 anti-tuberculosis
 drugs to which the patient's infection is known to be susceptible from recent drug
 susceptibility testing (DST) results (within the previous 6 months) or likely to be
 susceptible, based on known treatment history. The selection of the BR, including the number
 of companion drugs for TMC207, will be the responsibility of the investigator. At the
 screening visit, a completed inclusion/exclusion checklist list will be sent to the sponsor
 or its representative together with the patient's recent smear or culture and DST results
 (within preceding 6 months) and laboratory safety results to confirm eligibility. At
 baseline, a chest X-ray (CXR) will be taken in case no CXR or results of other imaging of the
 lungs are available within the previous month. Once treatment has been initiated, patients
 will be instructed to follow the visit schedule based on routine clinical care. Recommended
 visits and assessments should be planned 2, 4, 12, and 24 weeks following initiation of
 TMC207 in combination with the BR and 4 weeks (Week 28) and every 24 weeks (Weeks 48, 72, 96,
 and 120) after completion of TMC207 intake during the 96-week follow-up period. If needed,
 extra visits and assessments can be planned at the discretion of the investigator in order to
 best manage the patient's TB treatment. Patients who are taking clofazimine with TMC207 will
 require electrocardiogram (ECG) monitoring at mandatory protocol-specified visits. Serum
 chemistry (electrolytes) assessment will be performed at every visit in which an ECG is
 performed. After their last intake of TMC207, all patients will continue to take their BR
 under the supervision of their treating physician or local health center/hospital in
 accordance with NTP guidelines and local multi-drug resistant (MDR) TB treatment practice
 (i.e., treatment may be extended for reasons of complicated lung disease, etc.). Patients
 will be followed up for 96 weeks (2 years) after their last dose of TMC207 to evaluate the
 microbiological effect (verification of microbiological status [measured locally as per local
 standard of care; eg, smear, culture, DST] is recommended to be performed every 24 weeks)
 that TMC207 has provided these patients, as well as to monitor the safety and tolerability of
 TMC207. Patients who withdraw early, unless due to withdrawal of informed consent, will be
 followed for survival/clinical outcome (approximately every 6 months) until the early access
 study comes to an end in the patients' corresponding country. Patients can enter the study
 until TMC207 will be commercially available in the patient's country or can be accessed from
 another source or until discontinuation of the development program of TMC207.
Inclusion Criteria:

 -  Confirmed pulmonary XDR or pre-XDR-TB infection with resistance to INH, RMP, and to a
 FQ and/or injectable second line TB drug (kanamycin, amikacin, or capreomycin).
 Confirmation should include previous (within the preceding 6 months) smear or culture
 and drug susceptibility testing (DST) results demonstrating pulmonary TB with an XDR
 or pre-XDR resistance pattern

 -  Patient has limited or no treatment options and is unable/ineligible to participate in
 any other TMC207 study

 -  Patient will be managed at a medical center that has been certified by the Green Light
 Committee of the World Health Organization (WHO) Stop TB Partnership, OR, following an
 assessment of the site confirms that the site meets equivalent standards. Patients
 must be able to receive at least 3 anti-TB drugs to which the patient's infection is
 known to be susceptible from recent DST results (within the previous 6 months) or
 likely to be susceptible, based on known treatment history, per availability in the
 country

 -  Patient is medically stable in the opinion of the investigator on the basis of
 physical examination, and safety examinations performed at screening

 -  Patients must have signed an informed consent document indicating that they understand
 the purpose of and procedures required for the study and are willing to participate in
 the early access study

 Exclusion Criteria:

 -  History of and/or clinically relevant, currently active or underlying
 gastrointestinal, cardiovascular, nervous system, psychiatric, metabolic, renal,
 respiratory (other than due to TB), inflammatory, neoplastic, skin, immunological or
 infectious disease, which is not stable and controlled. If there are clinically
 relevant, currently active or underlying diseases, they should not compromise the
 safety of the patient or the ability to participate in the study as judged by the
 investigator. The investigator is encouraged to discuss concomitant illnesses with the
 sponsor

 -  Patients with complicated or severe extra-pulmonary manifestations of TB, including
 osteoarticular and central nervous system infection - Patients having received TMC207
 in a previous study

 -  Any condition that, in the opinion of the investigator, would compromise the early
 access study or the well-being of the patient or prevent the patient from meeting or
 performing protocol requirements

 -  Current alcohol, barbiturate, amphetamine, recreational or narcotic drug use, which in
 the investigator's opinion would compromise patient's safety and/or compliance with
 the protocol procedures

 -  Patients with any clinically significant electrocardiogram abnormality at screening

 -  Patients having received medications (within the last 7 days prior to Day 1) that have
 the potential of prolonging the QT interval